Stockscreener 앱 받기
0.5856
1.83%
0.0105
시간 외 거래:
.58
-0.0056
-0.96%
전일 마감가:
$0.5751
열려 있는:
$0.5699
하루 거래량:
6.99M
Relative Volume:
0.67
시가총액:
$162.68M
수익:
$2.02M
순이익/손실:
$-97.59M
주가수익비율:
-1.019
EPS:
-0.5747
순현금흐름:
$-102.38M
1주 성능:
+3.17%
1개월 성능:
+0.67%
6개월 성능:
-44.75%
1년 성능:
-67.28%
1일 변동 폭
$0.5699
$0.6078
1주일 범위
$0.54
$0.6078
52주 변동 폭
$0.5261
$2.55
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
0.5856 | 157.68M | 2.02M | -97.59M | -102.38M | -0.5747 |
VRTX
Vertex Pharmaceuticals Inc
|
508.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.85 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
990.32 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
154.04 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
190.95 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-27 | 개시 | Barclays | Overweight |
| 2025-05-14 | 재개 | H.C. Wainwright | Buy |
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Humacyte CEO to speak in New York on Sept. 16 - Stock Titan
Humacyte ATEV shows superiority in Phase 3 V012 study - scanx.trade
Hospitals can keep an emergency blood-vessel graft for 36 months, up from 18 - Stock Titan
HC Wainwright raises Humacyte price target to $4 - scanx.trade
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc.HUMA - Business Wire
Humacyte Inc. Warrant (HUMAW) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Humacyte Inc. Warrant (HUMAW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Humacyte Inc. Warrant (HUMAW) Peer Comparison – Compare with Others - Value Research
Humacyte plans November FDA filing for dialysis access use By Investing.com - Investing.com Nigeria
Humacyte Plans November 2026 Supplemental BLA Submission for ATEV Dialysis Access Based on Phase 3 Data - Quiver Quantitative
Humacyte plans November FDA filing for dialysis access use - investing.com
Price to sales forward of Humacyte, Inc. – NASDAQ:HUMA - TradingView
Investigation into Humacyte continues after FDA cites manufacturing violations and lawsuit proceeds. - Pluang
Humacyte Stock (HUMA) Opinions on Phase 3 Trial Results - Moomoo
Humacyte (HUMA) Shares: Records a 7.28% Decrease to $0.68 on the Day; Next Session - vinanet.vn
TD Cowen Maintains Humacyte(HUMA.US) With Buy Rating, Maintains Target Price $1.25 - Moomoo
Humacyte (HUMA) Q2 2026 Earnings Call Transcript - AOL.com
Humacyte publishes Phase 3 trial results in Lancet journal By Investing.com - Investing.com Australia
Humacyte publishes Phase 3 trial results in Lancet journal - Investing.com
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - The Manila Times
Humacyte Announces Lancet Digital Health Publication Of V007 Phase 3 Hemodialysis Access Trial Results - TradingView
A bioengineered vessel beat fistulas for women and men with obesity and diabetes on dialysis - Stock Titan
Fresenius Medical Care stock trades close to recent NYSE levels as Humacyte stake sale draws attenti - Ad-hoc-news.de
MSN Money - MSN
Major Humacyte (HUMA) holder sells shares under 10b5‑1 plan - Stock Titan
Humacyte Announces First Symvess Implants in Arizona by Phoenix Vascular Surgeon Jeromy Brink - Quiver Quantitative
A bioengineered blood vessel is ready off the shelf for urgent surgery - Stock Titan
HC Wainwright Predicts Humacyte's Q3 Earnings (NASDAQ:HUMA) - MarketBeat
Humacyte (NASDAQ:HUMA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Humacyte (HUMA) Faces A Fresh Test As Its $4 Fair Value Narrative Holds - Yahoo Finance
Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Price to book forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Enterprise value to EBITDA forward of Humacyte, Inc. – NASDAQ:HUMAW - TradingView
Benchmark Lowers Humacyte (NASDAQ:HUMA) Price Target to $1.00 - MarketBeat
Humacyte (HUMA) Stock Looks Stretched On Book Value Yet Reasonable After A 93% Fall - Yahoo Finance
Humacyte earnings missed by $0.07, revenue fell short of estimates - Investing.com Nigeria
Humacyte (HUMA) Reports Stronger Phase 3 Dialysis Results In Women - Yahoo Finance
Humacyte Q2 Revenue Rises to $0.4 Million as Net Loss Narrows - Moomoo
Humacyte Inc (HUMA) (Q2 2026) Earnings Call Highlights: Strong Trial Results and Strategic ... - Yahoo Finance Australia
Humacyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Humacyte, Inc. Q2 2026: Revenue $406K, EPS $(0.16) — 10-Q Summary - TradingView
Humacyte (NASDAQ: HUMA) logs $54.4M loss and flags going concern risk - Stock Titan
HUMA Q2 FY2026 earnings call - finance.biggo.com
Sutro Biopharma, Humacyte, CoreWeave - TradingView
Humacyte (NASDAQ:HUMA) Releases Quarterly Earnings Results - MarketBeat
Humacyte stock maintained at Buy by BTIG on pipeline progress - Investing.com Canada
Humacyte Q2 Results: Sales Miss Estimate by 64%, Loss Widens - scanx.trade
Earnings call transcript: Humacyte misses Q2 2026 estimates as shares fall premarket - Investing.com Nigeria
Humacyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
HUMA: Q2 2026 marked clinical breakthroughs, commercial momentum, and robust financial positioning - TradingView
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Humacyte Inc 주식 (HUMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Jones Keith Anthony | Director |
Aug 20 '26 |
Buy |
0.69 |
10,000 |
6,930 |
40,000 |
| Jones Keith Anthony | Director |
Aug 17 '26 |
Buy |
0.59 |
30,000 |
17,820 |
30,000 |
| Sebelius Kathleen | Director |
May 19 '26 |
Buy |
0.88 |
56,818 |
50,000 |
148,025 |
| Constantino Michael T. | Director |
May 18 '26 |
Buy |
0.89 |
11,000 |
9,840 |
43,950 |
| Sander Dale A. | CFO and Chief Corp. Dev. Off |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
267,213 |
| Parikh Shamik J | Chief Medical Officer |
May 18 '26 |
Sale |
0.90 |
45,887 |
41,147 |
272,713 |
0.88%
자본화:
|
볼륨(24시간):